ECOLAB INC. (ECL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $286.75, ECOLAB INC. (ECL) is priced for +22.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/ECL

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.2% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Ecolab's economics look less like a chemicals maker than a route business: field representatives install the dishwashers, water systems and pest programs, then sell what runs through them, which is why 22% of revenue arrives as service and lease income rather than as product sold.
• The price works out to roughly 32 times company-wide operating income, and the demand buried in that figure is duration rather than pace: profit has to keep compounding at the fastest rate the business can fund from its own cash flow for about five and a half more years.
• Second-quarter results land July 28, 2026, and the line to watch is the standoff between price and input costs, because in the March quarter the 10-Q recorded Underlying gross margin was stable as strong value pricing was offset by higher commodity costs.

Bull Case

The direction of travel is the argument here, not the level. In the March 2026 quarter the company reported Reported net sales increased 10% to $4,066.1 million and organic sales increased 4%. Underneath that, the Global Institutional & Specialty segment lifted its organic operating income margin by 1.8 percentage points, and the 10-Q is specific about where it came from: 2.7 points of value pricing, less 0.9 points spent back on investment in the business. Pricing did more work than volume, and it did that work while the company was funding its own expansion. Both engines running at once is rarer than it sounds.

What makes the pricing hold is the shape of the relationship. Ecolab does not sell a drum of chemistry and leave. It puts equipment into a hotel laundry, a food plant, a cooling tower or a hospital, then services it and sells the consumables that keep it running. Switching supplier means changing a process that has been validated and audited, often under food-safety or infection-control rules, which is a different decision from changing a commodity vendor. The FY2025 10-K describes the result plainly enough: Our retention rate of significant customers has aligned with our acquisition assumptions, a sentence about acquired customer bases that says the installed relationships survived the change of ownership.

The mix is also moving toward the parts that compound best. Organic sales for Global Pest Elimination increased 7% in the first quarter of 2026 driven by gains in restaurants, food retail, food & beverage and healthcare. Pest elimination is a pure service line with recurring contracts and route density that improves as the customer count rises. Meanwhile, effective January 2026 the company reorganized its reporting so that Global Life Sciences was elevated to a standalone reportable segment. That is management putting a growing, higher-margin business where investors can see it separately, which is usually a sign they expect the numbers to bear the scrutiny.

Capital allocation supports the same read. The company is not burning cash, operating income covers its interest bill about 8.8 times over, and the share count has been coming down at roughly 0.4% a year across the four years to March 2026. That is a slow retirement rather than an aggressive one, but it is real, and it means the growth the price requires is not being diluted away while it happens.

The bull case does not depend on Ecolab becoming a different company. It depends on the pricing mechanism that produced the March quarter continuing to work in a market where customers buy on validated performance rather than on unit cost, and on management keeping enough of that price after commodity costs take their share.

Bear Case

The moat is real, and it is being spent rather than banked. The clearest evidence sits in one sentence of the March 2026 10-Q: Underlying gross margin was stable as strong value pricing was offset by higher commodity costs. Strong pricing produced stability, not expansion. When a company with genuine switching costs pushes price hard and the result is a flat underlying margin, the pricing power is functioning as a defence against input inflation rather than as a source of widening returns. That is a materially different business from the one a top-of-cohort multiple implies.

Growth tells a similar story once acquisitions and currency are stripped out. Fixed currency sales were stable in 2025. In the March 2026 quarter, reported sales rose 10% while organic sales rose 4%, with acquisitions contributing 3 points and currency translation 4. Reported operating margin barely moved over the same comparison, up about a third of a percentage point. Buying growth and translating growth are both legitimate, but they are not the same asset as generating it, and the multiple is priced for the third kind.

Then there is the competitive question the company raises itself. The FY2025 10-K states that There can be no assurance that we will be able to accomplish our technology development goals or that technological developments by our competitors, including in the area of artificial intelligence, will not place certain of our products, technology or services at a competitive disadvantage in the future. A meaningful part of Ecolab's defensibility is the sensor-and-monitoring layer wrapped around the chemistry, the part that tells a customer their water loop or their kitchen is performing. That layer is software-shaped, and software-shaped advantages erode faster than chemistry patents do.

The external environment adds its own pressure. The same filing notes that Over the past year, changes in global trade policies, including the imposition of tariffs, import and export restrictions, and retaliatory trade actions, as well as implications of geopolitical situations in Europe, the Middle East, China, and Russia, have resulted in economic and demand uncertainty. For a business whose raw materials and finished goods cross borders continuously, that is a direct cost and volume risk, not background noise.

All of this matters because of what the price requires. Roughly 32 times company-wide operating income asks for profit growth at the ceiling the business can self-fund, sustained for about five and a half years, and only about 35% of comparable fast growers have historically held that pace over such a span. The multiple already sits at the very top of its peer distribution, well beyond the upper quartile. Meanwhile PG earns a 23.2% operating margin on $86.7 billion of revenue and CHD earns 17.3%, both comfortably above Ecolab's trailing operating margin of about 16.6%. If the duration assumption shortens by even a couple of years, the correction does not come out of the business. It comes out of the multiple, and the multiple is most of the price.

Valuation

Start with what the price is asking for. Ecolab's market value works out to about 32 times company-wide operating income, and running that backwards produces a requirement measured in time rather than in speed: operating profit compounding at the fastest rate the business can fund from its own cash flow, held there for roughly five and a half years. The rate itself is not the unusual part, since recent quarters have delivered it. The unusual part is the persistence, and the record on persistence is thin. Only about 35% of comparable fast growers sustained that level over a similar span.

None of the standard ways of valuing a business reaches today's price. The earnings-power methods, which capitalize what the company earns now and credit nothing further, sit at roughly a quarter of what the market pays, so the price stands at about four times that family's central estimate. The asset-value family, book value plus the return earned above the cost of equity, is about three and a half times below the price on the same reading. Peer multiples land closer, with the price at about two and a third times that family. Only the forward-growth methods come near, and the one that comes nearest does so by holding today's cash-profit multiple flat all the way out to its terminal year. Assuming the multiple never compresses is not an answer to the question the multiple poses.

The cohort comparison sharpens it. Ecolab's trailing operating margin runs about 16.6%. PG earns a 23.2% operating margin on $86.7 billion of revenue, and CHD earns 17.3%. The premium here is not being paid for current profitability, on which Ecolab trails both. It is being paid for the belief that the installed base converts into a longer runway of margin gains than a consumer-products peer can offer. Revenue mix is the one structural argument for that: in the March quarter product and equipment sales were $3,174.6 million and service and lease sales $891.5 million, and the service portion is the part that renews.

The balance sheet funds the bet without shortening it. Operating income covers the interest bill about 8.8 times over, cash generation is positive, and the share count has drifted down about 0.4% a year over four years, which is buyback deployment showing up where it cannot be faked. The debt is long and cheaply struck: the 10-Q shows long-term debt including current maturities of 8.19 billion dollars carried against a fair value of 7.35 billion dollars, the arithmetic of coupons fixed before rates moved. That combination bounds the downside on solvency. It does nothing for the duration assumption, which is where the price actually lives.

Catalysts

Second-quarter results are scheduled for July 28, 2026. Two lines from the March quarter set the test. The first is whether value pricing can move from holding underlying gross margin flat to expanding it, since the 10-Q attributed the March result to pricing being offset by higher commodity costs. The second is organic growth, which ran at 4% while reported sales rose 10%; the gap is acquisitions and currency, and only the organic figure speaks to the durability the price is paying for.

Sell-side positioning has moved decisively in one direction this year. Oppenheimer upgraded the shares to Outperform on ramping growth in July 2026, UBS moved to Buy from Neutral in May 2026, Citi opened a 90-day upside catalyst watch in late June 2026, and Deutsche Bank raised its target to $335 from $325 in July 2026. Those figures sit above where every standard valuation frame lands in this report, and the difference is what the street credits and these methods do not: acquisition contribution and a continuation of price-led margin gains carried forward rather than held flat.

One structural change is already filed rather than forecast. Effective January 2026 the company reorganized its reporting segments, folding its former healthcare business into Institutional and elevating Life Sciences to stand on its own. From the second quarter onward, investors get a separate line on the bioprocessing and pharmaceutical hygiene business, which the company reinforced with a new advanced development and applications centre in Korea announced in the spring. Cleaner disclosure cuts both ways: it will show the growth if the growth is there, and it will show the absence just as clearly.

Peer Cohorts (Per Segment, With Filing Citations)

Global Water (reported)

• KWR (QUAKER CHEMICAL CORPORATION)
• FY2025 10-K: $122.7 million in 2024, an increase of $4.3 million, or 4%, compared to 2023 as a result of improvement in net sales, partially offset by a decrease in segment operating margins. 40 Environmental Clean-up Activities The Company is involved in environmental clean-up activities in connection with an existing plant…
• FY2025 10-K: …Quaker Houghton is the global leader in industrial process fluids. With a presence around the world, including operations in over 25 countries, our customers include thousands of the world's most advanced and specialized steel, aluminum, automotive, aerospace, offshore, container, mining, and metalworking companies.…
• ECVT (Ecovyst Inc.)
• FY2025 10-K: …directly to customers. Our products are produced from readily available raw materials. We also use natural gas in our manufacturing process where our North American facilities have benefited from the plentiful supplies of shale gas. In addition, we have long-term contracts and relationships with many of our key raw…
• FY2025 10-K: …that we use for fuel. Accordingly, regulations controlling or limiting GHG emissions could have a material adverse effect on our business, financial condition or results of operations, including by reducing demand for our products. Sustainability initiatives may result in operational changes and expenditures, reduced…
• IOSP (INNOSPEC INC.)
• FY2025 10-K: …with developing customer needs. In addition, the business has developed further formulations in emollients, silicones and surfactants for the personal care, home care, agrochemical, construction, mining and other industrial markets. Fuel Specialties has continued to innovate, focused on bringing new technologies to…
• FY2025 10-K: …2025-01-01 2025-12-31 0001054905 iosp:QgpQuimicaGeralMember 2024-01-01 2024-06-30 0001054905 us-gaap:ConstructionInProgressMember 2025-12-31 0001054905 iosp:OtherNetIncomeExpenseMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2025-01-01 2025-12-31 0001054905…

Global Institutional & Specialty (reported)

• CLX (CLOROX CO /DE/)
• FY2025 10-K: …guidance issued by the U.S. Treasury Department, the U.S. Internal Revenue Service or similar bodies of state, local and foreign governments could create uncertainty, impact the Company's recorded liability in future periods and have a material impact on the Company's results of operations. For example, on July 4,…
• FY2025 10-K: …sentiment abroad, potentially resulting in targeted boycotts of U.S. products and services, which could adversely affect demand for the Company's products in certain international markets and negatively impact financial results. This uncertainty and volatility also make it difficult for the Company, as well as its…
• CHD (CHURCH & DWIGHT CO., INC.)
• FY2025 10-K: Breath, and (3) investing in our international businesses with a focus on M&A to grow from $1 billion to $2 billion. Our global product portfolio consists of both premium (66% of total worldwide consumer revenue in 2025) and value (34% of total worldwide consumer revenue in 2025) brands, which we believe enables us to…
• FY2025 10-K: 23%, 7% and 8%, respectively, of our 2025 international net sales in this segment. No product line accounts for more than 20% of our total international net sales. Some of our U.S. power brands such as ARM & HAMMER®, BATISTE®, HERO®, THERABREATH®, OXICLEAN®, TOUCHLAND® and WATERPIK® are distributed in many of our…
• CL (COLGATE-PALMOLIVE COMPANY)
• FY2025 10-K: …fees and costs that will be paid by us from Non-service related postretirement costs to Selling, general and administrative expenses. See Note 13, Commitments and Contingencies to the Consolidated Financial Statements for additional information. On July 31, 2025, our Board approved the Strategic Growth and…
• FY2025 10-K: …srt:MinimumMember cl:StrategicGrowthAndProductivityProgramMember 2025-12-31 0000021665 srt:AsiaPacificMember srt:MaximumMember cl:StrategicGrowthAndProductivityProgramMember 2025-12-31 0000021665 cl:AfricaEurasiaMember srt:MinimumMember cl:StrategicGrowthAndProductivityProgramMember 2025-12-31 0000021665…
• PG (PROCTER & GAMBLE CO)
• FY2025 10-K: …changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rates to demonstrate the potential impacts to the estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate, a 25…
• FY2025 10-K: …(OECD) issued "Pillar Two" model rules which established a global minimum corporate tax rate of 15% for large multinational corporations. Many countries have implemented or are in the process of implementing Pillar Two legislation into their respective domestic laws. Based on current legislation, available guidance…
• WDFC (WD-40 COMPANY)
• FY2025 10-K: …We are a meritocracy with a competitive performance-based total rewards strategy, where compensation and career advancement are determined by demonstrated competencies and contributions. Our calendar year 2023 global pay equity study reaffirmed there were not statistically significant or systemic gender-based pay…
• FY2025 10-K: …the interpretation of historical spending trends by customer and category, customer agreements and/or currently known factors that arise in the normal course of business. We review our assumptions and adjust these estimates accordingly on a quarterly basis. Our consolidated financial statements could be materially…

Global Life Sciences (reported)

• IFF (INTERNATIONAL FLAVORS & FRAGRANCES INC)
• FY2025 10-K: …pet food and feed additives. Food Ingredients also includes savory solutions (such as spices, marinades, and mixtures) and inclusion products (such as products combining flavorings with fruit, vegetables and other natural ingredients). Health & Biosciences Our Health & Biosciences segment consists of the development…
• FY2025 10-K: …are ultimately used by IFF's customers in a diverse variety of products, including savory products (soups, sauces, meat, fish, poultry, snacks, etc.), beverages (juice drinks, carbonated or flavored beverages, spirits, etc.), sweets (bakery products, candy, cereal, chewing gum, etc.), and dairy products (yogurt, ice…
• SXT (Sensient Technologies Corp)
• FY2025 10-K: …positions as of December 31, 2025. As part of its commitment to quality as a competitive advantage, the Company's production facilities hold various certifications, such as those under the International Organization for Standardization (ISO) and those recognized by the Global Food Safety Initiative (GFSI), including…
• FY2025 10-K: …for the Audit, Compensation and Development, Nominating and Corporate Governance, and Executive Committees of the Company's Board of Directors, as well as the Company's Code of Conduct, Corporate Governance Guidelines, Policy Relating to Recovery of Erroneously Awarded Compensation, and Non-Employee Directors and…
• BCPC (Balchem Corp)
• FY2025 10-K: …Discussion and Analysis of Financial Condition and Results of Operations under Item 7 below and in the Notes to our Consolidated Financial Statements included under Item 8 below, which information is incorporated herein by reference. Human Nutrition and Health The Human Nutrition and Health ("HNH") segment provides…
• FY2025 10-K: …competitive positions of certain of our products. Formulae and know-how are of particular importance in the manufacture of a number of our proprietary products. We believe that our patents, in the aggregate, are advantageous to our business. However, we do not believe we are materially dependent on any particular…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …emn:AdvancedMaterialsMember 2025-01-01 2025-12-31 0000915389 srt:AsiaPacificMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:AdvancedMaterialsMember 2024-01-01 2024-12-31 0000915389 srt:AsiaPacificMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember…
• FY2025 10-K: …2025-01-01 2025-12-31 0000915389 srt:LatinAmericaMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:FibersMember 2024-01-01 2024-12-31 0000915389 srt:LatinAmericaMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:FibersMember 2023-01-01…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.